MetaCap

Enveric Biosciences (ENVB) vs FibroBiologics (FBLG)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

FibroBiologics is the larger company by market cap ($6.3 million vs $6.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENVB-9.70%FBLG-38.16%
+4%-18%-40%
Oct 7, 20261 yearNov 20, 2026
ENVB-6.90%FBLG-37.61%
+7%-17%-40%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENVB versus FBLG key metrics
MetricENVBFBLG
Share price$1.35$0.705
Market cap$6.04M$6.34M
1-day change-4.26%-15.06%
EPS (TTM)$-13.01$-2.51
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.77M$-18.65M
52-week high$13.25$9.60
52-week low$1.17$0.62
Distance from 52-week high-89.81%-92.66%
Analyst consensus—none
Avg. price target upside—+1673.05%
Average volume56.55K160.05K
Shares outstanding4.48M8.99M
Employees515
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Enveric Biosciences

ENVB stock →

Enveric Biosciences, Inc., a biotechnology company, focuses on the development of small molecule neuroplastogenic therapeutics that address unmet needs in psychiatric and neurological disorders in the United States. Its lead drug candidate is EB-003, a novel derivative of DMT in preclinical development for mental health indications.

Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees

About FibroBiologics

FBLG stock →

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees

ENVB vs FBLG FAQ

Which is bigger, Enveric Biosciences or FibroBiologics?

FibroBiologics (FBLG) is larger, with a market capitalization of $6.34M compared with $6.04M for Enveric Biosciences (ENVB).

Are Enveric Biosciences and FibroBiologics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons